南洋行家论股
IHH医疗保健 富通购RHT估值合理
目标价：6.45令吉最新进展：
IHH医疗保健（IHH，5225，主板保健股）持股31%的印度富通医疗集团（Fortis Healthcare），昨日完成收购印度RHT医院资产。
共19家医院的收购价，总值27亿令吉，而所有医院都是位于富通目前营运的地点。
行家建议：
我们认为，富通收购RHT医院资产的估值合理，且有助减少富通的亏损。
过去，富通一直支付RHT庞大的医疗设备费用，截至3月的2020财年首半年内，支付了高达19亿印度卢比（约1.09亿令吉）费用，本身则面对达24亿印度卢比（约1.38亿令吉）亏损。
收购RHT后料可大幅度减少支付费用，并将改善盈利表现和现金流。
我们预计，富通收购RHT后，也将小幅提升IHH医疗保健的盈利，惟若全购富通活动完成，负债率会显著上升。
尽管如此，目前仅持有富通31%股权，联号公司亏损入账比较少，该不至于加重资产负债表。
http://www.enanyang.my/news/20190118/ihh医疗保健br-富通购rht估值合理/
Related Stocks
| Chart | Stock Name | Last | Change | Volume |
|---|
Market Buzz
2025-01-14
IHH2025-01-14
IHH2025-01-13
IHH2025-01-13
IHH2025-01-10
IHH2025-01-10
IHH2025-01-10
IHH2025-01-10
IHH2025-01-10
IHH2025-01-09
IHH2025-01-09
IHH2025-01-09
IHH2025-01-09
IHH2025-01-08
IHH2025-01-08
IHH2025-01-08
IHH2025-01-08
IHH2025-01-08
IHH
2025-01-07
IHH2025-01-07
IHH2025-01-07
IHH2025-01-07
IHHMore articles on 南洋行家论股
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
MQ Trading Signals
Time
Signal
Duration
Type
2025-01-15 12:05:00
EMA 5
5 Mins
SELL
2025-01-15 12:00:00
EMA 5
5 Mins
BUY
2025-01-15 11:35:00
EMA 5
5 Mins
SELL
2025-01-15 11:30:00
EMA 5
5 Mins
BUY
2025-01-15 11:30:00
ADX
5 Mins
BUY
Apps
Top Articles
1
2
Good Articles to Share
Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing (Correct)
3
Good Articles to Share
Evercore ISI's Julian Emanuel says its too early to buy weakness
4
Good Articles to Share
5
Good Articles to Share
6
Good Articles to Share
7
Good Articles to Share
Tens of thousands demonstrate in nationwide strike in Belgium | REUTERS
8
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
